Table 1.
Characteristics of studies in scoping review
| Characteristics | Reviewed studies (n = 91) |
|---|---|
| Publication year (1995–2020) | |
| Before 2013 | 25 (27) |
| 2013–2020 | 66 (73) |
| Number of countries | 38 |
| World region | |
| Latin America & Caribbean | 26 (29) |
| Sub‐Saharan Africa | 8 (9) |
| Middle East & North Africa | 19 (21) |
| Europe & Central Asia | 5 (5) |
| South Asia | 8 (9) |
| East Asia & Pacific | 25 (27) |
| Economic status a | |
| Upper‐middle income | 70 (77) |
| Lower‐middle income | 22 (24) |
| Low income | 2 (2) |
| Type of economic evaluation | |
| Cost analysis/Cost of illness | 44 (48) |
| Cost‐effectiveness/Utility analysis | 45 (49) |
| Cost minimization analysis | 2 (2) |
| Study design | |
| Observational | 41 (45) |
| Model‐based | 42 (46) |
| Experimental | 2 (2) |
| Other | 6 (7) |
| Evaluated intervention for cost estimation | |
| Diagnosis | 5 (5) |
| Treatment | 55 (60) |
| Diagnosis and treatment | 31 (34) |
| BC stages | |
| Early | 26 (29) |
| Advanced | 15 (16) |
| All | 44 (48) |
| Unknown | 1 (1) |
| Other (e.g., operable, node+) | 5 (5) |
| BC types | |
| Hormone receptor+ only | 13 (14) |
| HER2+ only | 19 (21) |
| Study perspective a | |
| Health care provider | 6 (7) |
| Health care payer | 20 (22) |
| Health care (not specified) | 29 (32) |
| Patient | 11 (12) |
| Societal | 23 (25) |
| Unknown | 10 (11) |
| Time horizon | |
| <1 year | 5 (5) |
| 1–9 years | 25 (27) |
| 10–19 years | 6 (7) |
| 20–39 years | 6 (7) |
| Lifetime or ≥ 40 | 19 (21) |
| Unknown | 30 (33) |
Data are presented as n (%).
a
Categories are not mutually exclusive, and percentages may sum up to more than 100%.
Abbreviations: BC, breast cancer; HER2, human epidermal growth factor receptor 2.